Compare USAS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | PVLA |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 29 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2004 | N/A |
| Metric | USAS | PVLA |
|---|---|---|
| Price | $4.56 | $129.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $6.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 4.1M | 237.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | $104,350.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $21.55 |
| 52 Week High | $10.50 | $151.18 |
| Indicator | USAS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 35.69 | 61.94 |
| Support Level | $3.53 | $109.68 |
| Resistance Level | $5.12 | $135.23 |
| Average True Range (ATR) | 0.38 | 6.89 |
| MACD | -0.05 | 2.16 |
| Stochastic Oscillator | 3.10 | 96.63 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.